CTI
  • Share
  • About Us
    • Vision & Values
    • Leadership
    • History
    • Collaborations
    • In the Community
    • Careers
    • Media Gallery
    • Contact CTI
  • Products
    • PIXUVRI®
  • Development
    • Pipeline
    • Pacritinib
    • Pixantrone
    • Tosedostat
    • Paclitaxel Poliglumex
    • Publications
  • Clinical Trials
    • Clinical Trial Overview
    • Physician Resources
    • Patient Resources
  • Investors
    • Overview
    • News
    • Stock
      • Stock Chart
      • Historical Price Lookup
      • Investment Calculator
      • Transfer Agent
    • SEC Filings
    • Analyst Coverage
    • Events & Webcasts
    • Annual Report
    • Shareholder Meeting
    • Financial Details
      • Trading Statistics
      • Balance Sheet
      • Income Statement
      • Cash Flow
      • Ratios
    • Corporate Governance
      • Committee Composition
      • Leadership Bios
      • Board of Directors
      • Governance Documents
      • Whistleblower Hotline
    • Investor FAQ
    • Information Request
    • Email Alerts

Investors

  • Overview
  • News
  • Stock
    • Stock Chart
    • Historical Price Lookup
    • Investment Calculator
    • Transfer Agent
  • SEC Filings
  • Analyst Coverage
  • Events & Webcasts
  • Annual Report
  • Shareholders Meeting
  • Financial Details
    • Trading Statistics
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Ratios
  • Corporate Governance
    • Leadership Bios
    • Board of Directors
    • Whistleblower Hotline
  • Investor FAQ
  • Information Request
  • Email Alerts

Info Tools

  • Print Page
  • Email Page
  • RSS Feed
  • Email Alerts
  • IR Contacts
  • Tear Sheet

Most Viewed Links

  • SEC Filings
  • CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
  • Events & Webcasts
  • Annual Report
  • Stock Quote

Definition

<< Back
Cash from Financing Activities
Cash From Financing Activities represents the sum of:
Financing Cash Flow Items
Cash Dividends Paid
Issuance (Retirement) of Stock, Net
Issuance (Retirement) of Debt, Net.

About CTI

  • Vision & Values
  • Leadership
  • History
  • Collaborations
  • In the Community
  • Careers
  • Media Kit
  • Contact CTI
  • Request Information

Products

  • PIXUVRI®

Development

  • Pipeline
  • Pacritinib
  • Pixantrone
  • Tosedostat
  • Paclitaxel Poliglumex
  • Publications

Clinical Trials

  • Clinical Trials Overview
  • Physician Resources
  • Patient Resources
  • Adverse Event Information

Investors

  • Investors Overview
  • News
  • Stock
  • SEC Filings
  • Analyst Coverage
  • Events & Webcasts
  • Annual Report
  • Financial Details
  • Corporate Governance
  • Investor FAQ

Conquering cancer. That's in our blood.

  • Follow us!
  • © 2019 CTI BioPharma Corp. CTI BioPharma and "Conquering cancer. That’s in our blood." are trademarks of CTI BioPharma Corp.
  • Terms of Use
  • Privacy Policy